The most ambitious form of treatment for AMN patients to date is the quantification of movement impairments.

The purpose of this study is to measure the time course of sensory loss and weakness and evaluate treatments in people with AMN. This is being done through the development of tests that are sensitive enough to detect defecits and track small changes in sensation and strength over 6 months to a year. Secondly, the further aim is to determine the relative contributions of sensory loss and weakness to balance and walking. Previously, doocumentation of AMN progression relied upon clinical observations and subjective rating scales that required 4 to 5 years to show change. This has made it difficult to evaluate small changes in sensation and strength, and has delayed assessment of therapeutic interventions...